rheumatoid%20arthritis
RHEUMATOID ARTHRITIS

Rheumatoid arthritis is a systemic autoimmune rheumatic disorder of unknown etiology.
It is the most common form of inflammatory arthritis.
Patient usually complains of joint pain and/or swelling with morning stiffness that lasts for more than an hour.

Goals of treatment are clinical & radiological remission of disease and to reduce functional limitations & permanent joint damage.

  1. Aletaha D, Neogi T, Silman AJ, et al. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/ European League Against Rheumatism collaborative initiative. Ann Rheum Dis. 2010 Sep;69(9):1580-1588. doi: 10.1136/ard.2010.138461. PMID: 20699241
  2. Furst DE, Breedveld FC, Kalden JR, et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007. Ann Rheum Dis. 2007 Nov;66(Suppl 3):iii2-iii22. PMID: 17934088
  3. Majithia V, Geraci SA. Rheumatoid arthritis: diagnosis and management. Am J Med. 2007 Nov;120(11):936-939. PMID: 17976416
  4. Felson DT, Smolen JS, Wells G, et al. American College of Rheumatology/European League Against Rheumatism provisional definition of remission in rheumatoid arthritis for clinical trials. Arthritis Rheum. 2011 Mar;63(3):573-586. doi: 10.1002/art.30129. PMID: 21294106
  5. Saag KG, Teng GG, Patkar NM, et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum. 2008 Jun;59(6):762-784. doi: 10.1002/art.23721. PMID: 18512708
  6. Smolen JS, Landewe R, Breedveld FC, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs. Ann Rheum Dis. 2010 Jun;69(6):964-975. doi: 10.1136/ard.2009.126532. PMID: 20444750
  7. Singh JA, Furst DE, Bharat A, et al. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2012 May;64(5):625-639. doi: 10.1002/acr.21641. PMID: 22473917
  8. National Institute for Health and Care Excellence. Adalimumab, etanercept, infliximab, rituximab and abatacept for the treatment of rheumatoid arthritis after the failure of a tumour necrosis factor inhibitor. NICE website. http://www.nice.org.uk/guidance/ta195/resources/guidance-adalimumab-etanercept-infliximab-rituximab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-after-the-failure-of-a-tnf-inhibitor-pdf. Aug 2010.
  9. National Institute for Health and Care Excellence. Adalimumab, etanercept, and infliximab for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta130/resources/guidance-adalimumab-etanercept-and-infliximab-for-the-treatment-of-rheumatoid-arthritis-pdf. Sep 2010.
  10. National Institute for Health and Care Excellence. Abatacept for treating rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs (rapid review of technology appraisal guidance 234). NICE website. http://www.nice.org.uk/nicemedia/live/14155/63676/63676.pdf. Apr 2013. Accessed 04 Jul 2013.
  11. Venables PJW, Maini RN. Clinical features of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Feb 2011. Accessed 15 Apr 2011.
  12. National Institute for Health and Care Excellence. Certolizumab pegol for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta186/resources/guidance-certolizumab-pegol-for-the-treatment-of-rheumatoid-arthritis-pdf. Feb 2010.
  13. UCB Pharma Inc. Certolizumab pegol: Highlights of prescribing information. http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/125160s0142lbl.pdf. 2008. Accessed 05 Jul 2013
  14. Schur PH, Maini RN, Moreland LW. General principles of management of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Feb 2011. Accessed 16 Apr 2011.
  15. Scottish Intercollegiate Guidelines Network. Management of early rheumatoid arthritis. SIGN. http://www.sign.ac.uk. Feb 2011. Accessed 15 Apr 2011
  16. Venables PJW, Maini RN. Diagnosis and differential diagnosis of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Nov 2010. Accessed 15 Apr 2011.
  17. National Institute for Health and Care Excellence. Rheumatoid arthritis: the management of rheumatoid arthritis in adults. NICE website. http://www.nice.org.uk/guidance/cg79/resources/guidance-rheumatoid-arthritis-pdf. Feb 2009.
  18. Schur PH, Maini RN, Gibofsky A. Nonpharmacologic and preventive therapies of rheumatoid arthritis. UptoDate Web Site. http://www.uptodate.com/index. Dec 2010. Accessed 15 Apr 2011.
  19. National Institute for Health and Care Excellence. Tocilizumab for the treatment of rheumatoid arthritis. NICE website. http://www.nice.org.uk/guidance/ta198/resources/guidance-tocilizumab-for-the-treatment-of-rheumatoid-arthritis-pdf. Aug 2010.
  20. Smolen JS, Landewé R, Breedveld FC, Buch M, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis. 2014 Mar;73(3):492-509. doi: 10.1136/annrheumdis-2013-204573. PMID: 24161836
  21. Smolen JS, Breedveld FC, Burmester GR, et al. Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Ann Rheum Dis. 2015 May. http://ard.bmj.com/content/early/2015/05/12/annrheumdis-2015-207524.full.pdf. PMID: 25969430
  22. Ritter J, Lewis L, Timothy M, Alberto F. Anti-inflammatory drugs and the treatment of arthritis. In: Hodder A. A Textbook in Clinical Pharmacology and Therapeutics. 5th ed. London, UK: Hodder Education; 2008:170.
  23. Singh JA, Saag KG, Bridges SL Jr, et al; American College of Rheumatology. 2015 American College of Rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken). 2016 Jan;68(1):1-25. doi: 10.1002/acr.22783. PMID: 26545825
  24. McInnes IB. Cytokine networks in rheumatic diseases: Implications for therapy. UptoDate. http://www.uptodate.com. Aug 2018.
  25. Moreland LW, Cannella A. General principles of management of rheumatoid arthritis in adults. UptoDate. http://www.uptodate.com. May 2018.
  26. Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet. 2016 Oct;388(10055):2023-2038. doi: 10.1016/S0140-6736(16)30173-8. PMID: 27156434
  27. Smolen JS, Landewé R, Bijlsma J, et al. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. PMID: 28264816
Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Rheumatology digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
04 Feb 2019
The carbon-chain length of saturated fatty acids appears to be an important factor in determining its role in cardiovascular health, a recent study has found.
5 days ago
Olanzapine confers a modest therapeutic effect on weight compared with placebo in adult outpatients with anorexia nervosa, a study has shown. However, it does not appear to offer significant benefit for psychological symptoms.
Pearl Toh, 2 days ago
A latest study at ISC 2019 shows that even patients with large-core stroke damage can have a good outcome after mechanical clot removal with endovascular thrombectomy (EVT), depending on the size of the infarct and time lapses between stroke onset and treatment.
Jairia Dela Cruz, 04 Feb 2019
Treatment with secukinumab results in a higher rate of remission or low-disease activity at week 16 in patients with psoriatic arthritis as compared with placebo, according to a posthoc analysis of the FUTURE 2 study. This effect is sustained at 2 years and is evident in both tumour necrosis factor inhibitor-experienced and -naïve patients.